{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:46:57Z","timestamp":1790632017072,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-62698-7","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T14:06:11Z","timestamp":1754575571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8083-247X","authenticated-orcid":false,"given":"Shipo","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-1919","authenticated-orcid":false,"given":"Busen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9216-4699","authenticated-orcid":false,"given":"Jianhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9303-8221","authenticated-orcid":false,"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-2645","authenticated-orcid":false,"given":"Jinlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-5177","authenticated-orcid":false,"given":"Zhenghao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-2639","authenticated-orcid":false,"given":"Xiaohong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-6844","authenticated-orcid":false,"given":"Yanjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-0024","authenticated-orcid":false,"given":"Xinghuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-2612","authenticated-orcid":false,"given":"Lihua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"62698_CR1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra2206573","volume":"387","author":"DH Barouch","year":"2022","unstructured":"Barouch, D. H. Covid-19 vaccines - Immunity, Variants, Boosters. N. Engl. J. Med. 387, 1011\u20131020 (2022).","journal-title":"N. Engl. J. Med."},{"key":"62698_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","volume":"11","author":"N Wu","year":"2023","unstructured":"Wu, N. et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir. Med. 11, 439\u2013452 (2023).","journal-title":"Lancet Respir. Med."},{"key":"62698_CR3","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1038\/s41591-023-02517-y","volume":"29","author":"S Chalkias","year":"2023","unstructured":"Chalkias, S. et al. Original SARS-CoV-2 monovalent and Omicron BA.4\/BA.5 bivalent COVID-19 mRNA vaccines: phase 2\/3 trial interim results. Nat. Med. 29, 2325\u20132333 (2023).","journal-title":"Nat. Med."},{"key":"62698_CR4","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S1473-3099(23)00746-6","volume":"24","author":"CH Hansen","year":"2024","unstructured":"Hansen, C. H. et al. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study. Lancet Infect. Dis. 24, e73\u2013e74 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"62698_CR5","doi-asserted-by":"publisher","first-page":"2400109","DOI":"10.2807\/1560-7917.ES.2024.29.10.2400109","volume":"29","author":"AJ Huiberts","year":"2024","unstructured":"Huiberts, A. J. et al. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. Euro Surveill 29, 2400109 (2024).","journal-title":"Euro Surveill"},{"key":"62698_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMc2215471","volume":"388","author":"DY Lin","year":"2023","unstructured":"Lin, D. Y. et al. Effectiveness of bivalent boosters against severe Omicron infection. N. Engl. J. Med. 388, 764\u2013766 (2023).","journal-title":"N. Engl. J. Med."},{"key":"62698_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2213907","volume":"388","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Antibody response to Omicron BA.4-BA.5 bivalent booster. N. Engl. J. Med. 388, 567\u2013569 (2023).","journal-title":"N. Engl. J. Med."},{"key":"62698_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","volume":"32","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe 32, 315\u2013321.e3 (2024).","journal-title":"Cell Host Microbe"},{"key":"62698_CR9","unstructured":"FDA news release. August 22, 2024., <https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently>"},{"key":"62698_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00654-6","volume":"8","author":"JM Knisely","year":"2023","unstructured":"Knisely, J. M. et al. Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report. NPJ Vaccines 8, 53 (2023).","journal-title":"NPJ Vaccines"},{"key":"62698_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S1473-3099(23)00350-X","volume":"23","author":"JX Li","year":"2023","unstructured":"Li, J. X. et al. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial. Lancet Infect. Dis. 23, 1143\u20131152 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"62698_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/infdis\/jiad338","volume":"229","author":"FZ Wang","year":"2024","unstructured":"Wang, F. Z. et al. An observational prospective cohort study of vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 infection of an aerosolized, inhaled adenovirus type 5-vectored coronavirus disease 2019 vaccine given as a second bBooster dose in Guangzhou city, China. J. Infect. Dis. 229, 117\u2013121 (2024).","journal-title":"J. Infect. Dis."},{"key":"62698_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","volume":"10","author":"JX Li","year":"2022","unstructured":"Li, J. X. et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir. Med. 10, 739\u2013748 (2022).","journal-title":"Lancet Respir. Med."},{"key":"62698_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S2213-2600(23)00049-8","volume":"11","author":"R Tang","year":"2023","unstructured":"Tang, R. et al. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir. Med. 11, 613\u2013623 (2023).","journal-title":"Lancet Respir. Med."},{"key":"62698_CR15","doi-asserted-by":"publisher","first-page":"1239179","DOI":"10.3389\/fimmu.2023.1239179","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients. Front. Immunol. 14, 1239179 (2023).","journal-title":"Front. Immunol."},{"key":"62698_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41590-024-01951-5","volume":"25","author":"M Gagne","year":"2024","unstructured":"Gagne, M. et al. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates. Nat. Immunol. 25, 1913\u20131927 (2024).","journal-title":"Nat. Immunol."},{"key":"62698_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-023-06951-3","volume":"626","author":"K McMahan","year":"2024","unstructured":"McMahan, K. et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature 626, 385\u2013391 (2024).","journal-title":"Nature"},{"key":"62698_CR18","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1473-3099(23)00199-8","volume":"23","author":"JD Wu","year":"2023","unstructured":"Wu, J. D. et al. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged >\/=18 years: a randomised, double-blind, phase 2b trial. Lancet Infect. Dis. 23, 1020\u20131030 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"62698_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2191738","volume":"12","author":"L Zheng","year":"2023","unstructured":"Zheng, L., Liu, S. & Lu, F. Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China. Emerg. Microbes Infect. 12, 2191738 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"62698_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","volume":"20","author":"SR Allie","year":"2019","unstructured":"Allie, S. R. et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat. Immunol. 20, 97\u2013108 (2019).","journal-title":"Nat. Immunol."},{"key":"62698_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41577-023-00897-3","volume":"24","author":"T Inoue","year":"2024","unstructured":"Inoue, T. & Kurosaki, T. Memory B cells. Nat. Rev. Immunol. 24, 5\u201317 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"62698_CR22","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","volume":"34","author":"AT Tan","year":"2021","unstructured":"Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728 (2021).","journal-title":"Cell Rep."},{"key":"62698_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","volume":"185","author":"PA Mudd","year":"2022","unstructured":"Mudd, P. A. et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185, 603\u2013613.e15 (2022).","journal-title":"Cell"},{"key":"62698_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","volume":"22","author":"EC Lavelle","year":"2022","unstructured":"Lavelle, E. C. & Ward, R. W. Mucosal vaccines - fortifying the frontiers. Nat. Rev. Immunol. 22, 236\u2013250 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"62698_CR25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"62698_CR26","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","volume":"387","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. A bivalent Omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279\u20131291 (2022).","journal-title":"N. Engl. J. Med."},{"key":"62698_CR27","doi-asserted-by":"publisher","first-page":"102442","DOI":"10.1016\/j.coi.2024.102442","volume":"88","author":"M Khamyath","year":"2024","unstructured":"Khamyath, M., Melhem, H., Balabanian, K. & Espeli, M. New insights into the mechanisms regulating plasma cell survival and longevity. Curr. Opin. Immunol. 88, 102442 (2024).","journal-title":"Curr. Opin. Immunol."},{"key":"62698_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.immuni.2022.03.003","volume":"55","author":"AJ MacLean","year":"2022","unstructured":"MacLean, A. J. et al. Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites. Immunity 55, 718\u2013733.e8 (2022).","journal-title":"Immunity"},{"key":"62698_CR29","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1073\/pnas.1115369109","volume":"109","author":"T Onodera","year":"2012","unstructured":"Onodera, T. et al. Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection. Proc. Natl. Acad. Sci. USA 109, 2485\u20132490 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62698_CR30","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1073\/pnas.1520112113","volume":"113","author":"C Havenar-Daughton","year":"2016","unstructured":"Havenar-Daughton, C. et al. CXCL13 is a plasma biomarker of germinal center activity. Proc. Natl. Acad. Sci. USA 113, 2702\u20132707 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62698_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2314808120","volume":"120","author":"S Miyamoto","year":"2023","unstructured":"Miyamoto, S. et al. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection. Proc. Natl. Acad. Sci. USA 120, e2314808120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62698_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).","journal-title":"Science"},{"key":"62698_CR33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/eji.1830140414","volume":"14","author":"FY Liew","year":"1984","unstructured":"Liew, F. Y. et al. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur. J. Immunol. 14, 350\u2013356 (1984).","journal-title":"Eur. J. Immunol."},{"key":"62698_CR34","doi-asserted-by":"publisher","first-page":"655896","DOI":"10.3389\/fcimb.2021.655896","volume":"11","author":"I Quinti","year":"2021","unstructured":"Quinti, I. et al. IgA antibodies and IgA deficiency in SARS-CoV-2 infection. Front. Cell. Infect. Microbiol. 11, 655896 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"62698_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0264-410X(95)93134-U","volume":"13","author":"T Tomoda","year":"1995","unstructured":"Tomoda, T. et al. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine 13, 185\u2013190 (1995).","journal-title":"Vaccine"},{"key":"62698_CR36","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41586-024-07729-x","volume":"632","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Turbinate-homing IgA-secreting cells originate in the nasal lymphoid tissues. Nature 632, 637\u2013646 (2024).","journal-title":"Nature"},{"key":"62698_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3389\/fimmu.2013.00222","volume":"4","author":"P Brandtzaeg","year":"2013","unstructured":"Brandtzaeg, P. Secretory IgA: designed for anti-microbial defense. Front. Immunol. 4, 222 (2013).","journal-title":"Front. Immunol."},{"key":"62698_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj5129","volume":"6","author":"JE Oh","year":"2021","unstructured":"Oh, J. E. et al. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Sci. Immunol. 6, eabj5129 (2021).","journal-title":"Sci. Immunol."},{"key":"62698_CR39","doi-asserted-by":"publisher","first-page":"2032057","DOI":"10.1155\/2020\/2032057","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. The effects of secretory IgA in the mucosal immune system. Biomed. Res. Int. 2020, 2032057 (2020).","journal-title":"Biomed. Res. Int."},{"key":"62698_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nri2322","volume":"8","author":"A Cerutti","year":"2008","unstructured":"Cerutti, A. The regulation of IgA class switching. Nat. Rev. Immunol. 8, 421\u2013434 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"62698_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.180784","volume":"9","author":"B Sun","year":"2024","unstructured":"Sun, B. et al. An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA. JCI Insight 9, e180784 (2024).","journal-title":"JCI Insight"},{"key":"62698_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063 (2021).","journal-title":"Science"},{"key":"62698_CR43","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"62698_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38744-7","volume":"14","author":"J Perez-Saez","year":"2023","unstructured":"Perez-Saez, J. et al. Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1\/BA.2 infection. Nat. Commun. 14, 3032 (2023).","journal-title":"Nat. Commun."},{"key":"62698_CR45","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMc2209651","volume":"387","author":"S Havervall","year":"2022","unstructured":"Havervall, S. et al. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. N. Engl. J. Med. 387, 1333\u20131336 (2022).","journal-title":"N. Engl. J. Med."},{"key":"62698_CR46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2666-5247(24)00025-9","volume":"5","author":"S Jackson","year":"2024","unstructured":"Jackson, S. et al. Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study. Lancet Microbe 5, 655\u2013668 (2024).","journal-title":"Lancet Microbe"},{"key":"62698_CR47","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2022.02.005","volume":"185","author":"S Afkhami","year":"2022","unstructured":"Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell 185, 896\u2013915.e19 (2022).","journal-title":"Cell"},{"key":"62698_CR48","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-023-06937-1","volume":"626","author":"I Uddback","year":"2024","unstructured":"Uddback, I. et al. Prevention of respiratory virus transmission by resident memory CD8(+) T cells. Nature 626, 392\u2013400 (2024).","journal-title":"Nature"},{"key":"62698_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01003-x","volume":"9","author":"CK Chew","year":"2024","unstructured":"Chew, C. K. et al. Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial. NPJ Vaccines 9, 209 (2024).","journal-title":"NPJ Vaccines"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62698-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62698-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62698-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:40:26Z","timestamp":1757346026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62698-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62698"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62698-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7281"}}